Cell salvage has been used as a method of blood conservation for more than
three decades. Although the principles and development of the Latham bowl h
ad occurred in the 1960s, it was not until the early 1970s that washing of
the concentrated red cells was introduced and a product that was universall
y acceptable was obtained. The last 25 years have seen little in the way of
development of cell salvage, although significant refinement has taken pla
ce. Although the simple picture of cell salvage involves removal of the buf
fy coat, including platelets and leucocytes, in practice there are reports
of great variation in the removal of these cells. Most recent studies sugge
st that there is very little removal of leucocytes by cell salvage. The leu
cocytes that remain in the red cell suspension following cell salvage have
undergone significant morphological changes and the surface expression of l
eucocyte adhesion receptors increases dramatically during the process. Ther
e is little evidence that removal of these activated leucocytes has any sig
nificant clinical benefit. Although leucofiltration of blood before storage
has been shown to be an extremely safe process, 'bedside leucofiltration',
including leucofiltration of cell salvage blood, may not be without proble
ms. Reports of hypotensive events while receiving blood products through a
bedside leucocyte reduction filter have emerged during the last few years.
This may be due to bradykinin production following platelet exposure to neg
atively charged leucocyte filters.